Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus

NCT ID: NCT00387309

Last Updated: 2019-11-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

495 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-12-31

Study Completion Date

2007-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary Objective: In subjects who have undergone segmental colectomy, the time between the end of surgery and first bowel movement is significantly shorter with the investigational MOA-728 regimen than with a placebo regimen.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post Operative Bowel Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Methylnaltrexone (MOA-728)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be scheduled for a segmental colectomy via open laparotomy with general anesthesia
* Subjects with history of inflammatory bowel disease are eligible as long as the disease is not currently active and all other criteria are met
* Subjects must meet the American Society of Anesthesiologists physical status I, II or III

Exclusion:

* Subjects who are scheduled for laparoscopic surgery for the segmental colectomy
* Subjects with a recent history (\<1 year prior to randomization) of abdominal radiation therapy; Subjects with a history of small bowel obstruction, known or suspected bowel adhesions (other than minor, clinically nonsignificant adhesions)
* Subjects undergoing operations resulting in gastrointestinal ostomies, or who require use of post operative nonsteroidal anti-inflammatory drugs (NSAIDs)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bausch Health Americas, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Salix Pharmaceuticals

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jeff Cohn

Role: STUDY_DIRECTOR

Bausch Health Americas, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mobile, Alabama, United States

Site Status

Fort Smith, Arkansas, United States

Site Status

Chula Vista, California, United States

Site Status

Colton, California, United States

Site Status

Los Angeles, California, United States

Site Status

Oceanside, California, United States

Site Status

Palo Alto, California, United States

Site Status

San Jose, California, United States

Site Status

Torrance, California, United States

Site Status

Denver, Colorado, United States

Site Status

Washington D.C., District of Columbia, United States

Site Status

Bay Minette, Florida, United States

Site Status

Jacksonville, Florida, United States

Site Status

Melbourne, Florida, United States

Site Status

Naples, Florida, United States

Site Status

St. Petersburg, Florida, United States

Site Status

Vero Beach, Florida, United States

Site Status

Weston, Florida, United States

Site Status

Atlanta, Georgia, United States

Site Status

Atlanta, Georgia, United States

Site Status

Marietta, Georgia, United States

Site Status

Chicago, Illinois, United States

Site Status

Chicago, Illinois, United States

Site Status

Naperville, Illinois, United States

Site Status

Park Ridge, Illinois, United States

Site Status

Kansas City, Kansas, United States

Site Status

Lexington, Kentucky, United States

Site Status

New Orleans, Louisiana, United States

Site Status

Hagerstown, Maryland, United States

Site Status

Boston, Massachusetts, United States

Site Status

Saint Paul, Minnesota, United States

Site Status

Saint Paul, Minnesota, United States

Site Status

Albany, New York, United States

Site Status

Kingston, New York, United States

Site Status

New York, New York, United States

Site Status

New York, New York, United States

Site Status

Syracuse, New York, United States

Site Status

Chapel Hill, North Carolina, United States

Site Status

Cleveland, Ohio, United States

Site Status

Columbus, Ohio, United States

Site Status

Zanesville, Ohio, United States

Site Status

Oklahoma City, Oklahoma, United States

Site Status

Bend, Oregon, United States

Site Status

Portland, Oregon, United States

Site Status

Danville, Pennsylvania, United States

Site Status

Hershey, Pennsylvania, United States

Site Status

Philadelphia, Pennsylvania, United States

Site Status

Pittsburgh, Pennsylvania, United States

Site Status

Wilkes-Barre, Pennsylvania, United States

Site Status

Pawtucket, Rhode Island, United States

Site Status

Providence, Rhode Island, United States

Site Status

Memphis, Tennessee, United States

Site Status

Nashville, Tennessee, United States

Site Status

Fort Worth, Texas, United States

Site Status

Fort Worth, Texas, United States

Site Status

San Antonio, Texas, United States

Site Status

Charlottesville, Virginia, United States

Site Status

Norfolk, Virginia, United States

Site Status

Winchester, Virginia, United States

Site Status

Camperdown, New South Wales, Australia

Site Status

Elizabeth Vale, South Australia, Australia

Site Status

Woodville South, South Australia, Australia

Site Status

Berlin, , Germany

Site Status

Halle, , Germany

Site Status

Heidelberg, , Germany

Site Status

München, , Germany

Site Status

Budapest, , Hungary

Site Status

Győr, , Hungary

Site Status

Pécs, , Hungary

Site Status

Székesfehérvár, , Hungary

Site Status

Osio Sotto, Zingonia, Italy

Site Status

Bologna, , Italy

Site Status

Ferrara, , Italy

Site Status

Genova, , Italy

Site Status

Monza, , Italy

Site Status

Padua, , Italy

Site Status

Roma, , Italy

Site Status

Katowice, , Poland

Site Status

Krakow, , Poland

Site Status

Lodz, , Poland

Site Status

Poznan, , Poland

Site Status

Bucharest, , Romania

Site Status

Bucharest, , Romania

Site Status

Bucharest, , Romania

Site Status

Bucharest, , Romania

Site Status

Beograd, , Serbia and Montenegro

Site Status

Pretoria, Gauteng, South Africa

Site Status

Pretoria, Gauteng, South Africa

Site Status

Pietermaritzburg, KwaZulu-Natal, South Africa

Site Status

Cape Town, Western Cape, South Africa

Site Status

Seoul, , South Korea

Site Status

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Germany Hungary Italy Poland Romania Serbia and Montenegro South Africa South Korea

References

Explore related publications, articles, or registry entries linked to this study.

Yu CS, Chun HK, Stambler N, Carpenito J, Schulman S, Tzanis E, Randazzo B. Safety and efficacy of methylnaltrexone in shortening the duration of postoperative ileus following segmental colectomy: results of two randomized, placebo-controlled phase 3 trials. Dis Colon Rectum. 2011 May;54(5):570-8. doi: 10.1007/DCR.0b013e3182092bde.

Reference Type DERIVED
PMID: 21471758 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3200L2-300

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.